Terms: = Bone cancer AND STAT5B, STAT5, 6777, ENSG00000173757, P51692 AND Prognosis
11 results:
1. Gab2 deficiency prevents Flt3-ITD driven acute myeloid leukemia in vivo.
Spohr C; Poggio T; Andrieux G; Schönberger K; Cabezas-Wallscheid N; Boerries M; Halbach S; Illert AL; Brummer T
Leukemia; 2022 Apr; 36(4):970-982. PubMed ID: 34903841
[TBL] [Abstract] [Full Text] [Related]
2. The IL-3, IL-5, and GM-CSF common receptor beta chain mediates oncogenic activity of FLT3-ITD-positive AML.
Charlet A; Kappenstein M; Keye P; Kläsener K; Endres C; Poggio T; Gorantla SP; Kreutmair S; Sänger J; Illert AL; Miething C; Reth M; Duyster J; Rummelt C; von Bubnoff N
Leukemia; 2022 Mar; 36(3):701-711. PubMed ID: 34750506
[TBL] [Abstract] [Full Text] [Related]
3. The delta isoform of phosphatidylinositol-3-kinase predominates in chronic myelomonocytic leukemia and can be targeted effectively with umbralisib and ruxolitinib.
Villaume MT; Arrate MP; Ramsey HE; Sunthankar KI; Jenkins MT; Moyo TK; Smith BN; Fischer MA; Childress MA; Gorska AE; Ferrell PB; Savona MR
Exp Hematol; 2021 May; 97():57-65.e5. PubMed ID: 33617893
[TBL] [Abstract] [Full Text] [Related]
4. Decreased expression of stat5A predicts poor prognosis in osteosarcoma.
Guo Z; Tang Y; Fu Y; Wang J
Pathol Res Pract; 2019 Mar; 215(3):519-524. PubMed ID: 30638860
[TBL] [Abstract] [Full Text] [Related]
5. Targeting stat5 or stat5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia.
Minieri V; De Dominici M; Porazzi P; Mariani SA; Spinelli O; Rambaldi A; Peterson LF; Porcu P; Nevalainen MT; Calabretta B
Cancer Res; 2018 Oct; 78(20):5793-5807. PubMed ID: 30154155
[TBL] [Abstract] [Full Text] [Related]
6. Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast cancer Predicts Poor Clinical Outcome and Correlates with Suppressed stat5 Signaling.
Tran TH; Utama FE; Sato T; Peck AR; Langenheim JF; Udhane SS; Sun Y; Liu C; Girondo MA; Kovatich AJ; Hooke JA; Shriver CD; Hu H; Palazzo JP; Bibbo M; Auer PW; Flister MJ; Hyslop T; Mitchell EP; Chervoneva I; Rui H
Clin Cancer Res; 2018 Dec; 24(24):6355-6366. PubMed ID: 30097435
[TBL] [Abstract] [Full Text] [Related]
7. Clinical features and the molecular biomarkers of olfactory neuroblastoma.
Peng X; Liu Y; Peng X; Wang Z; Zhang Z; Qiu Y; Jin M; Wang R; Kong D
Pathol Res Pract; 2018 Aug; 214(8):1123-1129. PubMed ID: 29921494
[TBL] [Abstract] [Full Text] [Related]
8. Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia.
Lim Y; Gondek L; Li L; Wang Q; Ma H; Chang E; Huso DL; Foerster S; Marchionni L; McGovern K; Watkins DN; Peacock CD; Levis M; Smith BD; Merchant AA; Small D; Matsui W
Sci Transl Med; 2015 Jun; 7(291):291ra96. PubMed ID: 26062848
[TBL] [Abstract] [Full Text] [Related]
9. A potential therapeutic target for FLT3-ITD AML: PIM1 kinase.
Fathi AT; Arowojolu O; Swinnen I; Sato T; Rajkhowa T; Small D; Marmsater F; Robinson JE; Gross SD; Martinson M; Allen S; Kallan NC; Levis M
Leuk Res; 2012 Feb; 36(2):224-31. PubMed ID: 21802138
[TBL] [Abstract] [Full Text] [Related]
10. The JAK2V617F allele burden and STAT3- and stat5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis.
Risum M; Madelung A; Bondo H; Bzorek M; Kristensen MH; Stamp IM; Hasselbalch HC
APMIS; 2011 Aug; 119(8):498-504. PubMed ID: 21749449
[TBL] [Abstract] [Full Text] [Related]
11. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia.
Lopes de Menezes DE; Peng J; Garrett EN; Louie SG; Lee SH; Wiesmann M; Tang Y; Shephard L; Goldbeck C; Oei Y; Ye H; Aukerman SL; Heise C
Clin Cancer Res; 2005 Jul; 11(14):5281-91. PubMed ID: 16033847
[TBL] [Abstract] [Full Text] [Related]
